Peregrine pharmaceuticals revenue.
Jul 15, 2017 · Peregrine Pharmaceuticals Inc.
Peregrine pharmaceuticals revenue. The report will be for the fiscal period ending January 31st, 2018. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company focused on developing novel investigational products that help harness the body's own immune system to fight cancer, today announced financial results for the fourth quarter and the fiscal year (FY) 2015 ended April 30 Jul 14, 2017 · Avid Bioservices Highlights "FY 2017 was a strong year for Avid Bioservices with year-over-year revenue growth of 30% compared to FY 2016. Jul 31, 2016 · PPHM has $62 million in cash and a debt free balance sheet. Evaluate their financials based on Peregrine Pharmaceutical's post-money valuation and revenue. 7% Y/Y) beats by $2. (“Peregrine”), a clinical stage biopharmaceutical company developing targeted therapeutics for the treatment of cancer and hepatitis C virus infection, and its wholly owned subsidiary, Avid Bioservices, Inc. 4 Million During Second Quarter FY 2017 with Contracted Backlog of Future Business Currently at $73 Million -- -- Beta-2 Glycoprotein-1 (β2GP1) Identified as a Dec 10, 2013 · TUSTIN, CA -- (Marketwired) -- 12/10/13 -- Peregrine Pharmaceuticals, Inc. Press Release This was corrected on 06/08/2022 at 5:05 AM. in January 2018. Find accurate contact data easily with LeadIQ. PPHMP preferred stock now yields 11. 63MM vs $44. Avid Bioservices had been a subsidiary that generated revenue for parent company's R&D Peregrine Pharmaceuticals is a public company that has been in the industry for 42 years. , and our wholly owned subsidiary, Avid Bioservices, Inc. Tarvacin Anti-Viral is designed for the treatment of hepatitis C infection, influenza, and other Jul 14, 2017 · July 14 (Reuters) - Peregrine Pharmaceuticals Inc * Peregrine Pharmaceuticals reports financial results for quarter and fiscal year ended April 30, 2017 and recent developments Jul 14, 2016 · Peregrine Pharmaceuticals (PPHM): FQ4 EPS of -$0. 9%. , a biopharmaceutical company focused on the development of first-in-class monoclonal antibodies for the treatment and diagnosis of cancer, today announced Sep 15, 2014 · Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a drug manufacturer that’s been in a proxy battle, said Roger J. Find related and similar companies as well as employees by title and much more. The Company delivers pharmaceutical products through its contract manufacturing business and through licensing its development-stage Nov 8, 2024 · Tustin, California-based Avid was the CDMO subsidiary of the former Peregrine Pharmaceuticals, a developer of antibody drugs for cancer. The company recognized revenue of $17. Data for Peregrine Pharmaceuticals | PPHM - Sales Revenues including historical, tables and charts were last updated by Trading Economics this last March in 2024. Peregrine Pharmaceuticals, Inc. 1 on the Business Journal’s 2009 list of fastest-growing public companies based here by posting a 380. and changed its name to Avid Bioservices, Inc. Peregrine repeated as No. with a focus on targeted treatments for cancer and viral diseases. Mar 7, 2016 · Peregrine Pharmaceuticals, Inc. In return, Avid receives $8 Jan 5, 2018 · For the twelve months ended April 30th, 2017 vs April 30th, 2016, Peregrine Pharmaceuticals reported revenue of $57. 95. 98M. Find employees, official website, emails, phone numbers, revenue, employee headcount, social accounts, and anything related to Peregrine Pharmaceuticals. Feb 17, 2025 · Peregrine’s main focus was drug development, however, its clinical trials for a cancer drug had failed and was losing the company tens of millions of dollars annually by 2017. (NASDAQ:PPHM) (NASDAQ:PPHMP), a company focused on continued revenue growth from its contract manufacturing business and developing its novel immuno-oncology products, today provided a corporate update highlighting the company's operational strategies and latest developments. The company's product candidates include Cotara and the Tarvacin line of products, which are in clinical trials and pre-clinical development. Sep 9, 2015 · Peregrine and AstraZeneca entered into a cancer immunotherapy clinical trial collaboration to evaluate bavituximab in combination with AstraZeneca’s investigational anti-PD-L1 immune checkpoint Mar 13, 2017 · -- Peregrine continues to execute its previously-announced strategy to reach sustained profitability by increasing contract manufacturing revenue while decreasing research and development expenses Peregrine Pharmaceuticals, Inc. until January 2018) [1] is a publicly-traded American contract manufacturing organization; it was formerly a biopharmaceutical company with a portfolio of monoclonal antibodies in clinical trials as potential cancer treatments and diagnostic agents. It operates as a Monoclonal antibodies for the treatment of different cancer such as brain, melanoma, adenocarcinoma. 78M (-45. is a biopharmaceutical company committed to improving the lives of patients by delivering high quality pharmaceutical products through its contract development and manufacturing organization (CDMO) services and through advancing and licensing its investigational immunotherapy and related products. 9 million for the fourth quarter and $57. Although Peregrine's pharmaceutical business Oct 4, 2009 · Peregrine Pharmaceuticals Inc. Dec 12, 2017 · Good day, ladies and gentlemen, and welcome to the Peregrine Pharmaceuticals Second Quarter Fiscal 2018 Financial Results Conference Call. (“Peregrine”), a biopharmaceutical company developing a portfolio of clinical stage and pre-clinical product candidates using monoclonal antibodies (“MAb”) for the treatment of cancer and viral diseases, and its wholly owned subsidiary, Avid Bioservices, Inc Oct 5, 2024 · Peregrine Pharmaceuticals, Inc. peregrinetrials. "While we missed our revenue guidance of $60 to $65 million, we were ready to ship a number of process validation runs which were delayed due to events outside our control. The company currently specializes in the Biotechnology, Pharmaceuticals areas. 6 million for the full fiscal year,” stated Paul Lytle, chief financial officer of Peregrine. For the fourth quarter, Peregrine announced revenue of $9. Jul 14, 2017 · Analyze up to 10 years of full 10K Annual Reports and Quarterly 10Q SEC filings for Peregrine Pharmaceuticals Inc (PPHM) using our online tools. , March 13, 2017 -- Peregrine Pharmaceuticals, Inc. Peregrine Pharmaceuticals is a Biotechnology, Business Services General, and Oncology Therapeutics company located in Tustin, California with $5. 05 misses by $0. May 1, 2024 · Peregrine Pharmaceuticals is a company located in Tustin, CA, United States. Create real-time notifications to follow any changes in the live stock price. The Income Statement (earnings report) for Peregrine Pharmaceuticals Inc Pref. has snapped up bavituximab and other phosphatidylserine-targeting assets from Avid Bioservices Inc. Revenue of $18. is a company focused on continued revenue growth from its contract manufacturing business and developing its novel immuno Mar 7, 2016 · The new Peregrine facility, which is being operated by Avid Bioservices, Inc. , a contract development and manufacturing organization (CDMO) previously known as Peregrine Pharmaceuticals Inc. was incorporated in 1981 and is based in Tustin, California. 3% Y/Y) misses by $0. 4% revenue growth rate for the 2)Ansoff Matrix of Peregrine Pharmaceuticals Inc Peregrine Pharmaceuticals Inc can use the Ansoff management tool to identify the revenue growth opportunities through exploring new markets or developing new products/services. Jul 14, 2017 · The company recognized revenue of $17. Peregrine Pharmaceuticals has raised an undisclosed amount in funding. NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Peregrine Pharmaceuticals | Nasdaq TUSTIN, CA – July 14, 2014 -- Peregrine Pharmaceuticals, Inc. 25M. Mar 9, 2016 · Peregrine Pharmaceuticals (PPHM): FQ3 EPS of -$0. Dec 25, 2017 · Tustin’s Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing high quality products for biotechnology and pharmaceutical companies, and advancing its proprietary R&D pipeline, today announced financial results for the third See Peregrine Pharmaceutical funding rounds, investors, investments, exits and more. Dec 10, 2013 · Peregrine Pharmaceuticals, Inc. Peregrine Pharmaceuticals Inc is a company focused on continued revenue growth from its contract manufacturing business and developing its novel immuno-oncology products. Mar 12, 2009 · Peregrine Pharmaceuticals of Tustin, CA, has posted financial results for its 2009 third quarter. The accompanying interim condensed consolidated financial statements include the accounts of Peregrine Pharmaceuticals, Inc. 69MM (up 28. This Annual Report contains “forward-looking statements” within the meaning of Section 27A of Jul 14, 2017 · The company recognized revenue of $17. Sep 11, 2017 · Shares in Peregrine Pharmaceuticals Inc. Revenue of $6. maintained initial contract manufacturing revenue guidance of $18 million to $22 million for the entire fiscal year of 2014. 02. The Avid Bioservices, formerly Peregrine Pharmaceuticals, provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. is a publicly-traded American biopharmaceutical company with a portfolio of monoclonal antibodies in clinical trials as potential cancer treatments and diagnostic agents. -- Avid Posts Record Revenue of $23. Dec 10, 2014 · Peregrine Pharmaceuticals, Inc. Dec 13, 2016 · Peregrine Pharmaceuticals (PPHM) Q2 2017 Earnings Conference Call December 12, 2016 4:30 PM ETExecutivesTim Brons - IR, Vida Strategic PartnersSteve King - Peregrine Pharmaceuticals, Inc. Tustin-based Peregrine reached No. For fiscal 2015, the company expects contract manufacturing revenue to be in the range of $19 and $23 million. It also has a revenue-generating subsidiary, Avid Bioservices, which is a contract manufacturing organization that provides services to Peregrine Pharmaceuticals Revenue to Assets of financial indicators from Balance Sheet, Income Statement and Peregrine Pharmaceuticals Statement of Cash Flow Avid Bioservices (known as Peregrine Pharmaceuticals, Inc. 08 misses by $0. is a biopharmaceutical company developing therapeutics to stimulate the body's immune system to fight cancer. peregrineinc. In 2018, Peregrine decided to end its drug R&D and focus Learn more about Peregrine Pharmaceuticals's company details, contact information, competitors, and more. 71M (+18. Book a demo today. is a biopharmaceutical company committed to improving the lives of patients by delivering high quality pharmaceutical products Mar 13, 2017 · TUSTIN, Calif. , a wholly owned subsidiary of Peregrine, will more than double the company’s prior manufacturing capacity Mar 7, 2016 · Completing a project started 15 months ago, Peregrine Pharmaceuticals commissioned a plant in California this week that more than doubles the company's biologics manufacturing capacity and adds Peregrine Pharmaceuticals Inc SEC 10-Q filing for January 31, 2016. Jun 2, 2016 · About Peregrine Pharmaceuticals, Inc. Press Release Jul 14, 2016 · In addition, this revenue growth came entirely from Avid’s first manufacturing facility and the company is positioned for continued revenue growth with the launch of its second manufacturing facility that became fully operational in March 2016” stated Paul Lytle, chief financial officer of Peregrine. Peregrine Pharmaceuticals Inc generates approximately USD 35,200,000 in revenue annually, and employs around 250 people at this location. 31 misses by $0. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company focused on the development of first-in-class monoclonal antibodies for the treatment and diagnosis of cancer, today announced financial results for the fourth quarter and the fiscal year (FY) 2014 ended April 30, 2014 and -- Peregrine continues to execute its previously-announced strategy to reach sustained profitability by increasing contract manufacturing revenue while decreasing research and development expenses View today's Avid Bioservices Inc stock price and latest CDMO news and analysis. Jul 14, 2014 · Peregrine Pharmaceuticals, Inc. doesn’t yet have a commercial drug on the market, but that hasn’t stopped it from growing. Feb 13, 2018 · Boston-based oncology therapeutics company Oncologie Inc. 4M in Sales Revenues for its fiscal quarter ending in September of 2023. Jul 14, 2017 · Based on this current backlog, Peregrine expects contract manufacturing revenue for FY 2018 to be between $50 and $55 million. (PPHM) Q1 2018 Earnings Conference Call September 11, 2017 4:30 PM ETExecutivesSteven King - President and CEOPaul Lytle - Dec 15, 2016 · Peregrine reported strong fiscal 2Q 2017 financial results beating analysts' estimates of revenues and net income by a wide margin. Revenue of $12. Use the CB Insights Platform to explore Avid Bioservices's full profile. At this time, all participants are in a listen-only mode TUSTIN, CA – July 14, 2015 -- Peregrine Pharmaceuticals, Inc. David Sherris is the primary contact at Peregrine Pharmaceuticals Inc. The company is focused on evaluating its lead CDMO Avid Bioservices Inc Peregrine Pharmaceuticals Reports Financial Results for Quarter and Fiscal Year Ended April 30, 2016 and Recent Developments The accompanying interim condensed consolidated financial statements include the accounts of Peregrine Pharmaceuticals, Inc. Jul 15, 2017 · Peregrine Pharmaceuticals Inc. See what kind of people work at Peregrine Pharmaceuticals, career paths working at Peregrine Pharmaceuticals, company culture, salaries, employee political affiliation, and more. Aug 11, 2015 · For the fourth quarter, Peregrine announced revenue of $9. (PPHM) Q4 2017 Earnings Conference Call July 14, 2017 4:30 PM ETExecutivesTim Brons - Investor RelationsSteven King - Jul 14, 2017 · The company recognized revenue of $17. TUSTIN, Calif. The company maintains its manufacturing revenue guidance for the full FY 2018 of $50 million - $55 million. View EPS, revenue, and EBIT data to support smarter investment decisions on Tiger Brokers' website. These patents also provide Peregrine Pharmaceuticals Inc with licensing revenue when it licenses these patents out to other manufacturers. Shares +5%. 76M. Avid Bioservices is a world-class CDMO, offering services in PD, analytical, manufacturing, and Quality and Regulatory compliance. 97%) and basic earnings per share -$0. Find the company's financial performance, revenue, and more. 5 million in revenue. 1 on the Business Journal’s 2010 list of fastest-growing public companies based in Orange Mar 7, 2016 · -- Facility Being Operated by Avid Bioservices Subsidiary with Capacity to Potentially Generate Additional $40 Million in Annual Revenue -- TUSTIN, CA, March 7, 2016 -- Peregrine Pharmaceuticals, Dec 11, 2017 · Peregrine Pharmaceuticals (PPHM): Q2 EPS of -$0. 01. 78M (+101. Find contact information for Peregrine Pharmaceuticals. . Find out what it's like to work at Peregrine Pharmaceuticals. 33M Other current liabilities: 669K See Full Balance Sheet Stay updated on Peregrine Pharmaceuticals (PPHM) earnings dates, reports, and calls. PPHM Financial Facts Interest and other income: 25K Cost of contract manufacturing: 3. Find the latest highlights on Peregrine Pharmaceuticals at the Nasdaq stock exchange. The Peregrine Pharmaceuticals Inc VRIO Analysis shows that Peregrine Pharmaceuticals Inc’s distribution network is a valuable resource. Spending on Bavituximab development has been slashed. The annual revenue of Peregrine Pharmaceuticals was $116 million in 2024. Jun 2, 2016 · Peregrine Pharmaceuticals, Inc. (“Avid”), which performs contract manufacturing of Jul 14, 2015 · View differences made from one year to another to evaluate Peregrine Pharmaceuticals Inc's financial trajectory Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables wereremoved,addedandby Peregrine Pharmaceuticals Inc. is a company focused on continued revenue growth from its contract manufacturing business and developing its novel immuno-oncology products. Although Peregrine's pharmaceutical business Jun 2, 2016 · About Peregrine Pharmaceuticals, Inc. (“Avid”). As of 2016 their lead product candidate was bavituximab. 19. 31 million in contract manufacturing revenue from its subsidiary Avid Bioservices, a 44% Peregrine Pharmaceuticals (ZB_36830556. Peregrine Pharmaceuticals reported $25. Review the company's financial statements, management discussion, market risks and other disclosures. Lias is the company’s new chief executive and president. (PGID) stock quote, history, news and other vital information to help you with your stock trading and investing. View Peregrine Pharmaceuticals (www. Feb 4, 2025 · The company was formerly known as Peregrine Pharmaceuticals, Inc. , a biopharmaceutical company focused on advancing bavituximab, a new immuno-oncology antibody targeting the highly immunosuppressive phosphatidylserine signaling Analyze the Peregrine Pharmaceuticals Inc Pref income statement, including revenue, gross profit, operating income, and net income. Oct 29, 2024 · Avid Bioservices, formerly Peregrine Pharmaceuticals, is a biopharmaceutical company, which is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts. In 2018, the company pivoted from developing drugs to becoming a pure CDMO, manufacturing biologics for pharmaceutical companies, and changed its name to Avid. This results in greater revenue for Peregrine Pharmaceuticals Inc. Avid Bioservices, Inc. Sep 11, 2017 · Peregrine Pharmaceuticals, Inc. provided revenue guidance for the fiscal year of 2015. is a biopharmaceutical company based in Tustin, Calif. has grown with contract manufacturing and government business as it works on developing drugs for fighting viral diseases and cancer. Mar 13, 2017 · -- Peregrine continues to execute its previously-announced strategy to reach sustained profitability by increasing contract manufacturing revenue while decreasing research and development expenses Jul 14, 2014 · View differences made from one year to another to evaluate Peregrine Pharmaceuticals Inc's financial trajectory Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables wereremoved,addedandby Peregrine Pharmaceuticals Inc. , June 02, 2016 ( ) -- Peregrine Pharmaceuticals, Inc. Learn about their Manufacturing market share, competitors, and Peregrine Pharmaceuticals's email format. is a biopharmaceutical company with a pipeline of novel drug candidates in clinical trials focused on the treatment of cancer. Apr 27, 2025 · Peregrine Pharmaceuticals is a public company based in Tustin (United States), founded in 1981. 06M See Full Income Statement Accumulated deficit: -520. About Peregrine Pharmaceuticals, Inc. The company is focused on evaluating its lead immunotherapy candidate, bavituximab, in combination with a range of novel immuno-oncology (I-O) agents for the treatment of various cancers. 1% Y/Y) misses by $1. Oct 2, 2010 · Tustin-based Peregrine Pharmaceuticals Inc. Mar 12, 2015 · Peregrine Pharmaceuticals (PPHM) shares are rising in after-hours trading after the company reported its third quarter financial results after the closing bell. In Tuesday midday trading the drugmaker gave back some of those gains. in Tustin rose 12% in intraday trading Monday and rose another 4% after hours on a nearly four-fold increase in revenue and a sharply lower quarterly loss; trading volume on the day was three times its 90-day average. 7 million in revenue and 49 employees. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced financial results for the second quarter of fiscal year (FY) 2014 ended October 31, 2013 and provided an update on its advancing clinical pipeline and other PART I In this Annual Report on Form 10-K (the “Annual Report”), unless the context otherwise indicates, the terms “we,” “us,” “our,” “Company” and “Peregrine” refer to Peregrine Pharmaceuticals, Inc. Peregrine Pharmaceuticals is expected to report earnings on March 12th, 2018. com) location in California, United States , revenue, industry and description. 3 million, a 44% increase from the year-ago period when it reported $6. Jun 2, 2016 · The latest news vindicates our bullish calls and signals what we believe is a new bull run getting started for PPHM. Press Release Find the latest Peregrine Industries, Inc. 88 vs -$1. Jan 5, 2018 · For the twelve months ended April 30th, 2017 vs April 30th, 2016, Peregrine Pharmaceuticals reported revenue of $57. The company's contract manufacturing subsidiary Jan 5, 2018 · Peregrine Pharmaceuticals Announces Name Change to Avid Bioservices as Part of Transition to Dedicated Contract Development and Manufacturing Organization (CDMO) Company Adopts “CDMO” as New Peregrine expects third-party contract manufacturing revenue for the entire fiscal year to exceed $40 million. Peregrine Pharmaceuticals' results, by the numbers For the quarter, Peregrine Pharmaceuticals generated $9. Total costs and expenses for the fourth quarter of FY 2017 were $23,208,000, compared to $30,698,000 for the fourth quarter of FY 2016. zjmurbiblne5l9pn4nu9r9iavihhi5zc5anaj7wtpgzwnylbw3